Evidence map›Paper›PMID 35481691›Full record

Trial reportNeurogastroenterology and motility2022

Transcutaneous vagal nerve stimulation protects against stress-induced intestinal barrier dysfunction in healthy adults.

Tamara Mogilevski, Sam Rosella, Qasim Aziz, Peter R Gibson

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Neurogastroenterology and motility, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 30 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Tamara MogilevskiDepartment of Gastroenterology, Monash University and Alfred Health, Melbourne, Australia.ORCID 0000-0002-8954-2978
Sam RosellaDepartment of Gastroenterology, Monash University and Alfred Health, Melbourne, Australia.
Qasim AzizBarts Health NHS trust, London, UK.
Peter R GibsonDepartment of Gastroenterology, Monash University and Alfred Health, Melbourne, Australia.
Alfred Health · AUQueen Mary University of London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntestinal barrier dysfunction is the likely initiating event in multiple human diseases. Currently, there are limited therapeutic strategies to address its dysfunction. Animal studies suggest that vagal nerve stimulation may improve intestinal barrier function, but this has not been evaluated in humans. This study aimed to determine the effect of vagal nerve stimulation on intestinal permeability in adults administered a bolus dose of intravenous corticotropin releasing hormone (CRH) which has been shown to increase small intestinal permeability in healthy human subjects.

methodsIn a cross-over study, 16 volunteers (median age 34 years, 11 female) were randomized to receive auricular transcutaneous vagal nerve or sham stimulation (10 minutes each side) after intravenous administration of 100 µg of CRH. Intestinal barrier function was measured before and 2 h after each intervention with dual-sugar urine testing (lactulose:mannitol ratio) and intestinal fatty-acid binding protein (I-FABP). KEY

resultsExposure to CRH increased I-FABP concentrations by a median of 49 (IQR 4-71)% (p = 0.009). Lactulose:mannitol ratios were 0.029 (0.025-0.050) following vagal stimulation compared with 0.062 (0.032-0.170) following sham stimulation (p = 0.0092), representing a fall of 53 (22-71)%. I-FABP concentrations did not change (p = 0.90).

conclusionsBrief non-invasive vagal nerve stimulation consistently reduces paracellular permeability of the small intestine after CRH administration, but does not entirely mitigate I-FABP release from the epithelium. Studies of vagal nerve stimulation in disease states are warranted.

Indexed as

Intestinal DiseasesVagus Nerve StimulationAdultAnimalsCorticotropin-Releasing HormoneCross-Over StudiesFemaleHumansIntestinal MucosaLactuloseMannitolCorticotropin-Releasing HormoneLactuloseMannitolcorticotropin releasing hormone (CRH)intestinal barrier dysfunctionintestinal fatty acid binding protein (I-FABP)transcutaneous vagal nerve stimulationurine dual sugar test

Identifiers

PMID35481691
PMCPMC9786250
OpenAlexW4224999578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.